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SUMMARY. Medication adherence is important for the suc-
cess of nucleos(t)ide analogue (NUC) treatment for chronic
hepatitis B. The aims of this study were to determine
adherence to NUCs and factors associated with NUC
adherence and to correlate NUC adherence with the
occurrence of virological breakthroughs in patients with
chronic hepatitis B. Consecutive patients with chronic
hepatitis B receiving NUC were asked to complete a survey
every 3 months. Adherence was also assessed by health-
care providers in the clinic. Adherence rate was defined as
the per cent of days the patients took their hepatitis B virus
medications during the last 30 days. A total of 111
patients were studied. The mean age was 47.7 years,
73.9% were men, 57.7% were Asian, 42.3% had post-
graduate education and 80% had private insurance. Sixty-
nine (74.1%) patients reported 100% adherence in the
survey, while 78 (83.9%) reported 100% adherence to
their healthcare providers. Patients with 100% adherence
based on the survey were older (P = 0.02), more likely to
be men (P = 0.006), and had higher annual household
income (P = 0.04) than those with <100% adherence. In
the 80 patients who completed three surveys, viral break-
through was observed in 1/46 (2.2%) with 100% adher-
ence on all three surveys, 1/18 (5.6%) with <100%
adherence on one survey and 3/16 (18.8%) with <100%
adherence on ‡2 surveys, (P = 0.06). In conclusion,
adherence to NUC therapy in our patients with chronic
hepatitis B was high but self-reporting of adherence to
healthcare providers may be inflated. Patients with chronic
hepatitis B with better adherence to NUC therapy had a
trend towards a lower rate of viral breakthroughs.
Keywords: antiviral resistance, antiviral therapy, HBV DNA,
hepatitis B treatment.
INTRODUCTION
There are seven approved therapies including five nucle-
os(t)ide analogues (NUCs) and two interferon alpha formu-
lations for the treatment of chronic hepatitis B (CHB). NUCs
have potent antiviral activity, are administered orally and
have very few side effects but they do not eradicate hepatitis
B virus (HBV). Therefore, most of the patients require long
durations of treatment to maintain viral suppression and to
achieve clinical benefit. Long duration of treatment is asso-
ciated with increasing risk of drug resistance. Analysis of
phase III clinical trials of NUCs found that virological
breakthrough (VBT) occurred in 1.6–13.8% of patients after
1 year of treatment; however, genotypic resistance (GR) was
not confirmed in any of the patients who experienced VBT
while receiving NUCs that have high genetic barrier to
resistance, such as entecavir and tenofovir [1–7]. These
results suggest that a major cause of VBT may be poor
adherence to medications.
Medication adherence has been shown to correlate with
clinical response and treatment outcome in many medical
conditions [8–12]. Studies in patients receiving nonboosted
protease inhibitor-based regimens for human immunodefi-
ciency virus (HIV) infection found that near-perfect adher-
ence (‡95%) was required to maintain viral suppression and
to prevent drug resistance, whereas moderate to high levels
of adherence (70–95%) to non-nucleoside reverse trans-
criptase inhibitor-based regimens was sufficient for optimal
virological response [12–15]. Similarly, hypertensive
patients with at least 80% adherence to antihypertensive
agents were less likely to develop coronary artery disease,
cerebrovascular disease and congestive heart failure, and
hypercholesterolaemic patients with at least 90% adherence
to statins had fewer nonfatal coronary artery events [9,10].
Abbreviations: CHB, chronic hepatitis B; GR, genotypic resistance;
HBV, hepatitis B virus; HIV, Human immunodeficiency virus; NUCs,
nucleos(t)ide analogues; VBT, virologic breakthrough.
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Data on medication adherence in patients receiving NUCs for
CHB are limited. Our previous study using a national phar-
macy claims database of 11 100 subjects found that the
mean adherence rate during a 1-year period was
87.8 ± 19.1% [16]. Because the database was not linked to
any clinical information, the relationship between adherence
and virological response or breakthrough could not be
determined.
The aims of the current study were (i) to determine
medication adherence using a standardized questionnaire
among patients receiving NUCs for CHB, (ii) to determine the
factors associated with medication adherence, (iii) to corre-
late medication adherence with VBT and confirmed GR and
(iv) to correlate self-reported adherence with provider
assessment of medication adherence.
MATERIALS AND METHODS
Study patients
Adult patients with chronic hepatitis B receiving NUCs
attending the liver clinic at the University of Michigan
Health System were eligible to participate in this study.
Exclusion criteria included patients with hepatitis C, hepa-
titis D or HIV co-infection; patients with decompensated liver
disease or prior liver transplantation; patients with impaired
renal function requiring dose adjustment of NUC; immuno-
suppressed patients receiving HBV antiviral prophylaxis;
pregnant patients; and patients who were not fluent in
English or were unable to provide consent.
Study design
This study was conducted between May 2009 and October
2010. The protocol was approved by our institutional review
board. Eligible patients were enrolled during a scheduled
clinic visit. At enrolment, patients were asked to complete a
confidential questionnaire and return to the research fellows
(WC and CH) who were not involved in the care of the
patients. The healthcare providers (6 hepatology faculty and
2 physician assistants) also assessed the participants medi-
cation adherence during the clinic visit and documented the
information in the clinic notes. Patients were asked to
complete a shorter version of the questionnaire every
3 months for up to 1 year. Medical records of each patient
were reviewed to retrieve information regarding medical
history, current and previous HBV treatments and virologi-
cal response and breakthroughs.
Self-reported questionnaire
The initial questionnaire collected data on demographic,
education, household income; HBV treatments, health
insurance and copayment for HBV medication (see sup-
plementary Table S1). In addition, patients were asked four
questions relating to medication adherence, the key ques-
tion being how many days they missed their HBV medi-
cation in the last 30 days. The follow-up questionnaire (see
supplementary Table S2) collected data on current HBV
treatment and three questions relating to medication
adherence.
Definitions
Adherence was defined as the per cent of days in which the
patients took their NUC medication during the given period
[17]. In this study, adherence was assessed every 3 months
and data from the last 30 days were used as an approxi-
mation of the patients medication behaviour during the
3-month period covered by each questionnaire [18,19].
Patients who indicated they did not miss a single dose of
HBV medication during the last 30 days were considered to
have perfect adherence.
Virological response was assessed by monitoring serum
HBV DNA every 3–6 months. Serum HBV DNA was quan-
tified by real-time polymerase chain reaction assays, COBAS
TaqMan HBV (Roche Diagnostics, Indianapolis, IN, USA)
with a lower limit of detection of 29 IU/mL. When VBT was
detected, serum HBV DNA was retested after 1–3 months
and antiviral drug-resistance mutation was tested in those
with confirmed VBT. Antiviral drug-resistance mutations
were determined by direct sequencing as described previ-
ously [20].
VBT was defined as an increase in serum HBV DNA by
‡1 log10 above nadir or 10 times the lower limit of detection
in patients who had undetectable HBV DNA previously, while
on treatment. Confirmed VBT was defined as the persistence
of VBT on repeat test at least 1 month later. GR was defined
as the detection of signature mutations associated with
resistance to the HBV medication the patient was receiving.
Statistical analyses
Continuous variables were expressed as mean ± SD, or
median and range. Categorical variables were expressed as
number and percentage. Mann–Whitneys test was used to
compare continuous variables, while Fishers exact test was
used for categorical data. In all cases, comparisons were two-
tailed, and a P-value of <0.05 was considered statistically
significant. The data analyses were performed using SPSS
software version 18 (SPSS, Chicago, IL, USA).
RESULTS
A total of 159 patients with chronic hepatitis B receiving
NUC were seen during the study period. Thirty-three patients
were excluded for the following reasons: not fluent in English
(n = 15), impaired renal function requiring dose adjustment
of HBV medication (n = 6), decompensated liver disease or
transplantation for CHB (n = 4), immunosuppression
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requiring HBV prophylaxis (n = 3), HIV or hepatitis C virus
co-infection (n = 5) and mental disability (n = 2). Thirteen
patients declined participation and the most common rea-
sons cited were not wanting to disclose their data (n = 4)
and not having enough time to complete the questionnaire
(n = 5).
Baseline characteristics of patients
A total of 111 patients were enrolled; 73.9% were men, and
the mean age was 47.7 ± 13.1 years. Approximately, half
(57.7%) were Asian. Almost half of the patients (42.3%) had
a postgraduate degree, 39.7% were professionals and
approximately 40% of the patients reported an annual
household income of more than $100 000 USD (Table 1).
The mean duration of known HBV infection was
13.3 ± 8.2 years. More than half (56.7%) of the patients had
received prior HBV treatment. A variety of treatment regi-
mens were usedwith 84 patients receiving NUCmonotherapy
and 27 NUC combinations. The mean duration of the current
HBV treatment regimen was 36.7 ± 32 months; 23.4% of
patients had been on the current HBV treatment for <1 year,
while 15.3% had been on the current treatment formore than
5 years. Most of the patients (80%) had private insurance that
covered their HBVmedication, and themedian copayment per
month was $20 (range, $0–360) (Table 2).
Table 1 Demographic and socioeconomic data of patients
at enrolment
Characteristics n = 111
Age (years)
Mean ± SD 47.7 ± 13.1
Median (range) 49 (19–73)















Some high school or high
school graduate
16 (14.4)
Some college or college
graduate
48 (43.3)
Postgraduate degree 47 (42.3)
Occupation
Student 10 (9)
Not in workforce or homemaker 23 (20.7)




Annual household income (USD)
£20 000 17/107 (15.9)
20 001–60 000 30/107 (28.0)
60 001–100 000 18/107 (16.8)
>100 000 42/107 (39.3)
Results expressed as number (%) or mean ± SD unless
specified otherwise.
Table 2 Medical history and HBV treatment at enrolment
Characteristics n = 111
Duration of known HBV infection (years)
Mean ± SD 13.3 ± 8.2
Previous HBV treatment
None 48 (43.3)
1 regimen 24 (21.6)
‡2 regimens 39 (35.1)
Payment for HBV medication
Private insurance 88/110 (80)
Medicare/medicaid 13/110 (11.8)
Own money 2/110 (1.8)
Other 7/110 (6.4)
Copay (USD/month)
Mean ± SD 36.9 ± 58.6
Median (range) 20 (0–360)
Other chronic illness
None 64 (57.7)
1 disease 24 (21.6)
‡2 diseases 23 (20.7)
Number of prescribed oral pills per day*
None 41 (37)
1 pill 21 (18.9)








Other combination 11 (9.9)
Duration of current HBV treatment (months)
Mean ± SD 36.7 ± 32
Median (range) 26 (3–181)
Results expressed as number (%) or mean ± SD unless
specified otherwise. *Not including HBV medications.
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Adherence to HBV medication
At enrolment, the mean adherence rate based on self-
reporting was 98.2 ± 3.8%. Eighty-one (73%) patients
reported that they did not miss any dose of HBV medication
in the last 30 days (perfect adherence), while 14.4%, 6.3%
and 6.3% reported that they missed their HBV medication on
1, 2 and more than 2 days, respectively, in the last 30 days
(Fig. 1). Of the seven patients who missed their HBV medi-
cation more than 2 days, three missed their HBV medication
on 3 days, one on 4 days, two on 5 days and one on 6 days.
Adherence rates remained stable during the course of the
study. At the time when the study was closed, 96, 86, 71 and
41 patients had completed the follow-up questionnaire at
months 3, 6, 9 and 12, respectively, and the rates of perfect
adherence at these time points were 78.1%, 80.2%, 77.5%
and 73.2%, respectively. Thirty-seven patients completed all
five questionnaires through month 12, 15 patients reported
perfect adherence on each occasion, eight patients reported
less than perfect adherence through enrolment and perfect
adherence on all (n = 3) or some questionnaires during fol-
low-up (n = 5), while 12 patients reported perfect adherence
initially and less than perfect adherence on ‡1 questionnaires
during follow-up. Only two patients reported less than perfect
adherence on all occasions.
Adherence rates reported in confidential questionnaire vs
adherence rates reported to healthcare provider
At enrolment, 93 (83.8%) patients had documentation of
adherence assessment by their healthcare providers. Sev-
enty-eight patients reported to their healthcare provider that
they did not miss any dose of HBV medication in the last
30 days but only 69 (88.5%) of these 78 patients reported
perfect adherence in the confidential questionnaire (Fig. 2).
Reasons for missing HBV medication
At enrolment, 30 patients reported that they missed their
HBV medication on ‡1 days during the last 30 days. The
most common reasons why HBV medication was missed
were forgetfulness (n = 20) and travelling away from home
(n = 4).
Factors associated with perfect adherence at study
enrolment
Patients with perfect adherence at enrolment were more
likely to be men and to be older and had a higher annual
household income (Table 3). Race, education, occupation,
duration of known HBV infection, type of current HBV
medication, history of previous treatment, type of health
insurance, copayment for HBV medication, presence of
comorbid medical conditions and number of other prescribed
oral pills were not different between the two groups.
Correlation between adherence rate and virological
breakthrough and genotypic resistance
At enrolment, 85 patients had been on the current HBV
treatment regimen for >12 months. Of these, 45 of 63
(71.4%) patients with 100% adherence and 17 of 22
(77.3%) patients with <100% adherence had undetectable
HBV DNA (P = 0.78).
Eighty (72.1%) patients completed all three questionnaires
at months 0, 3 and 6. Forty-six (57.5%) patients reported
perfect adherence on all three questionnaires (group 1), 18
Fig. 1 Adherence at enrolment based on self-reported
questionnaire (n = 111). Pie diagram showing the per cent
of patients who missed 0, 1, 2 or >2 doses of hepatitis B
virus nucleos(t)ide analogue during a 30-day period prior to
enrolment.
Fig. 2 Comparison of adherence based on self-reported
confidential questionnaire and healthcare provider assess-
ment (n = 93). Columns showing the per cent of patients
who missed 0, 1, 2 or >2 doses of hepatitis B virus nucle-
os(t)ide analogue during a 30-day period prior to
enrolment.
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Table 3 Characteristics of patients with





rate = 100% P value
Total patients 30 81
Age (years)
Mean ± SD 43.2 ± 12.5 49.4 ± 13.1 0.02
Gender (male) 16 (53.3) 66 (81.5) 0.006
Race
Caucasian 9 (30) 31 (38.3) 0.27
Asian 17 (56.6) 47 (58)
African American 2 (6.7) 2 (2.5)
Other 2 (6.7) 1 (1.2)
Education
Postgraduate degree 9 (30) 38 (46.9) 0.13
Other 21 (70) 43 (53.1)
Occupation
Professional 9 (30) 35 (43.2) 0.51
Other 21 (70) 46 (56.8)
Annual household income (USD)
<20 000 7 (23.3) 10/77 (13) 0.04
20 001–60 000 9 (30.0) 21/77 (27.3)
60 001–100 000 6 (20) 12/77 (15.6)
More than 100 000 8 (26.7) 34/77 (44.1)
Duration of known hepatitis B virus (HBV) infection (years)
Mean ± SD 11.7 ± 6.7 13.8 ± 8.7 0.36
Other chronic illness
None 21 (70) 43 (53.1) 0.13
‡1 disease 9 (30) 38 (46.9)
Number of oral pills per day*
None 12 (40) 29 (35.8) 0.79
‡1 pill 18 (60) 52 (64.2)
Previous HBV treatment
None 14 (46.7) 34 (42) 0.51
‡1 regimen 16 (53.3) 47 (58)
Duration of current HBV treatment (months)
Mean ± SD 35.2 ± 29.5 37.3 ± 33 0.94
Type of insurance
Private insurance 21/29 (72.4) 67 (82.7) 0.11
Other 8/29 (27.6) 14 (17.3)
Copay (USD/month)
Mean ± SD 29.3 ± 41.8 39.7 ± 63.9 0.29
Results expressed as number (%) or mean ± SD unless specified otherwise. *Not
including HBV medications. Variables that were statistically significant are given
in bold.
 2011 Blackwell Publishing Ltd
Adherence to HBV treatment 209
reported <100% adherence on one of the three question-
naires (group 2), and 16 reported <100% adherence on at
least two of the three questionnaires (group 3). During the
first 6 months after enrolment, VBT was observed in one
patient (2.2%) in group 1, one patient (5.6%) in group 2 and
3 patients (18.8%) in group 3 (P = 0.06) (Fig. 3). Of the
three patients who experienced VBT in group 3, two had
confirmed VBT on retesting. VBT was not confirmed in the
third patient in group 3 and the two patients in groups 1 and
2. None of the patients with VBT had evidence of antiviral
drug-resistance mutations by direct sequencing. Serum HBV
DNA decreased in all five patients during continued treat-
ment with the same medication.
DISCUSSION
In this study, we found that adherence to NUCs in patients
with CHB being treated in an outpatient hepatology clinic
was very high. Based on responses to the confidential
questionnaire, the mean adherence rate was 98% and 73%
of patients reported that they did not miss a single dose of
medication during the past 30 days. The adherence rate
based on patients report to healthcare providers was even
higher (99%), and 84% of patients indicated that they did
not miss a single dose of medication during the past 30 days.
These adherence rates were higher than the 87.8% adher-
ence rate among existing patients in our previous study of a
nationwide prescription refill database [16].
Several factors may explain the very high rate of adher-
ence to HBV NUCs observed in this study. First, adherence
based on self-reporting may be inflated. Studies that com-
pared medication adherence based on self-reporting with
adherence assessed by other methods such as medication
electronic monitoring systems and pill count have found
adherence rates based on self-reporting to be 10–30% higher
[21]. In this study, we found that when adherence was
assessed simultaneously, patients reported higher rates of
adherence to their healthcare providers than what they
recorded in a confidential questionnaire. Another reason for
the high adherence rate in this study may be related to the
fact that most of our patients were highly educated, affluent,
with good health insurance and low copayment for their
medications. Other studies have shown that low educational
level, lack of prescription coverage and high copayment for
medications are associated with lower adherence rate to
medications [22–25]. A third possible explanation for the
high adherence rate is that our patients were seen in a ter-
tiary clinic and monitored by an experienced team of hepa-
tologists, physician assistants and nurses who are committed
to the care of patients with viral hepatitis. Indeed, 78% of
our patients indicated that their healthcare providers played
a primary role in reminding them the importance of taking
their HBV medications daily.
Comparison of the patients with and without 100%
adherence found that patients with perfect adherence were
older, more likely to be men and had higher annual
household income. Several studies also found a higher rate
of adherence to HIV treatment, statins and antihypertensive
drugs among older patients [16,26–28]. Older patients may
be more concerned about preserving their health or they
may be aware that they are at higher risk of complications
from chronic HBV infection. Several previous studies
revealed that women had higher adherence to medications
than men [28–30]. One potential explanation why we found
a higher adherence rate among men is that many of our
patients may have been aware that men with chronic HBV
infection have a higher risk of developing cirrhosis and
hepatocellular carcinoma.
The adherence rate to NUC remained high during the
study period (mean adherence rate 97.7–99.1%), although
we acknowledge that only 64% and 36.9% of the cohort had
been followed to months 9 and 12, respectively. Of the 80
patients who completed the questionnaire at enrolment,
month 3 and month 6, 46 (58%) reported 100% adherence
on all three questionnaire, while 16 (20%) reported that
they missed at least one dose in two of the three question-
naire. The latter patients were more likely to experience VBT
than those with consistently perfect adherence (19% vs 2%,
P = 0.05). Testing for GR failed to reveal any antiviral drug-
resistance mutation and serum HBV DNA decreased in all
patients during continued treatment, supporting the notion
that the VBTs were secondary to nonadherence to NUC.
These data highlight the importance of educating patients on
the importance of adherence to HBV NUC and the need for
programmes to assist patients in remembering to take their
medications. Our findings also underscore the importance of
confirmation of VBT by retesting serum HBV DNA and/or
confirmation of GR before changing treatment. The associ-
ation between transient treatment interruption and viral
rebound and antiviral drug resistance has also been reported
Fig. 3 Correlation between medication adherence and
occurrence of virological breakthrough (VBT). Data shown
for 80 patients who completed all three questionnaires at
enrolment, month 3 and month 6.
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in the studies of patients receiving non-nucleoside reverse
transcriptase inhibitor-based treatment for HIV infection
[31–33].
This study has several limitations. First, the number of
patients studied was small. Second, the study population was
highly educated and affluent. Third, patients who were not
fluent in English were excluded. Fourth, the patients were
managed in a tertiary liver centre by an experienced team
with a long-standing interest in hepatitis B treatment. Thus,
the results in this study may be a best-case scenario and
cannot be generalized to other patient populations. Finally,
objective methods to verify adherence reported in the ques-
tionnaire and healthcare provider assessment were not used.
Nevertheless, this is the first study to examine adherence to
HBV NUC in a cohort of more than 100 patients with CHB in
clinical practice and its association with the occurrence of
VBT. In addition to patient self-reporting using a confidential
questionnaire, adherence was simultaneously assessed by
healthcare providers in clinic. Furthermore, adherence was
assessed serially over a period of up to 12 months in a
subgroup of patients.
In conclusion, adherence to NUC therapy in our patients
with CHB was very high but self-reporting of adherence to
healthcare providers may be overestimated. Patients who
maintained 100% adherence to NUC therapy had a trend
towards a lower rate of VBT. Our data highlight the
importance of education on medication adherence to
improve the effectiveness of HBV treatment in clinical
practice and provide insights into how adherence may be
augmented.
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